Metraipolis › archive › dc_bb691003989b

Sacituzumab govitecan as a therapeutic breakthrough in the treatment of triple-negative breast cancer: a systematic review of clinical trials — Europe PMC PMID:41601628

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41601628
DOI
10.3389/fimmu.2025.1679648
License (as archived)
solo-consultazione
Archived
2026-11-06T21:21:30.790Z
SHA-256 of the archived text
9da6ed6fc29e541ab5620c1943001a5edff828bca4758d8b261b22758fde48ed
Stable URL of this page
https://metraipolis.com/documento/dc_bb691003989b

How to cite

Sacituzumab govitecan as a therapeutic breakthrough in the treatment of triple-negative breast cancer: a systematic review of clinical trials — Europe PMC PMID:41601628 — Europe PMC (en), https://europepmc.org/article/MED/41601628 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bb691003989b (Metraipolis archive dc_bb691003989b, sha256 9da6ed6fc29e541ab5620c1943001a5edff828bca4758d8b261b22758fde48ed)
BibTeX
@misc{dcbb691003989b,
  title = {Sacituzumab govitecan as a therapeutic breakthrough in the treatment of triple-negative breast cancer: a systematic review of clinical trials — Europe PMC PMID:41601628},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41601628},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bb691003989b; sha256 9da6ed6fc29e541ab5620c1943001a5edff828bca4758d8b261b22758fde48ed},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41601628. Agents can read the archived copy with the MCP tool read_document.